The contents
of this lecture presentation include : Vaccines can prevent viral disease, Why
are there so few antiviral drugs?, Antiviral history, Blind screening, Antiviral
discovery today, The path of drug discovery, Mechanism-based screens, Cell-based
screen, Antiviral screening, High throughput screening, Dangers of drug
resistance, Mechanisms of drug resistance, Acyclovir mechanism of action,
Improving acyclovir, Acyclovir-resistant HSV, Symmetrel, Influenza virus NA
inhibitors, WIN compounds, Inhibitors of picornavirus uncoating, New HCV drugs,
HCV new drug pipeline, Azido-deoxythymidine, AZT, Non-nucleoside RT inhibitors,
IN inhibitors, Maraviroc: CCR5 inhibitor, Combination therapy, Mathematics of
drug resistance, ART saves lives, Pre-exposure prophylaxis.
Author(s): Prof. Vincent Racaniello, Columbia University
This volume evaluates the carcinogenic
risk to humans posed by infections with human immunodeficiency viruses types 1
and 2 (HIV-1 and HIV-2) and human T-cell lymphotropic viruses types I and II (HTLV-I
and HTLV-II).
Author(s): National
Center for Biotechnology Information, U.S
This note explains the following topics: The origin
of virology, Virus structure, Enveloped virus, Genomes, Viral genomes and
classification of viruses.
This note explains the following topics: structure,
classification, repliation and viral interference, Group V viruses, Negative
sense single stranded RNA viruses, Morbilli virus, Orthomyxo viruses, Equine
flu, nature of the virus, disease and its pathogenesis, diagnosis and various
lab tests, vaccines, Zoonotic potential, Impacts of swine flu, Negative sense
RNA viruses, morphology and the nature of the virus.